Sab Biotherapeutics Inc (SABS) Stock Price, Quote & News

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte glo...

Industry: Biotechnology

Sector: Healthcare

Phone: 605 679 6980

Website: www.sabbiotherapeutics.com

Address:

777 W 41st St., Miami Beach, United States

stockboyaisle1 Dec. 13 at 10:59 PM

$SABS any news from the Asia conference?

1 · Reply

DDiamond_Handz Dec. 11 at 6:10 PM

$SABS if this isn't a buy signal I dont know what is

0 · Reply

DDiamond_Handz Dec. 10 at 12:37 AM

$SABS before new years, if not shortly after

0 · Reply

JTebow_CWS Dec. 8 at 11:45 PM

$SABS $SABSW $SNY Powerhouse clinical team.

0 · Reply

stockanalysis_ Dec. 8 at 9:27 PM

After Hours Losers: $ORKT $TWG $BDRX $SABS $CMCT Bookmark this page: https://stockanalysis.com/markets/afterhours/losers/?ref=saveontrading

0 · Reply

DDiamond_Handz Dec. 8 at 8:01 PM

$SABS a whale wants cheap shares, should bounce right back

0 · Reply

don_111 Dec. 8 at 7:17 PM

$SABS Getting smoked today. Maybe some are locking profits before the data presentation "just in case"?!

1 · Reply

JTebow_CWS Dec. 8 at 6:31 PM

$SABS They wouldn’t be sharing this data if it was poor results. SAB Biotherapeutics (SABS) announced that the Company will give several oral presentations at the 2nd Asian Conference on Innovative Therapies for Diabetes Management being held December 9-11, 2025, in Singapore. Data to be presented will highlight the progress of SAB BIO’s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for delaying the progression of T1D in new-onset, Stage 3 patients, including: Phase 1 study data showcasing the clinically validated, multi-specific mechanism of action of SAB-142. Phase 1 study data demonstrating immunomodulation without sustained lymphodepletion following dosing of SAB-142. Phase 1 study data demonstrating a favorable safety profile for SAB-142, characterized as not causing serum sickness or anti-drug antibodies at the target dose.

0 · Reply

Quid_Pro_Quo Dec. 8 at 6:13 PM

$SABS Usually after such a drop a big spike a around the corner

0 · Reply

JTebow_CWS Dec. 8 at 5:19 PM

$SABS https://ir.sab.bio/news-releases/news-release-details/sab-bio-present-data-showcasing-progress-development-sab-142/

0 · Reply

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

Nov 13, 2025, 5:00 PM EST - 4 weeks ago

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

Nov 4, 2025, 8:30 AM EST - 5 weeks ago

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

Nov 4, 2025, 8:00 AM EST - 5 weeks ago

SAB BIO to Participate in Upcoming Investor Conferences

Sep 19, 2025, 7:24 AM EDT - 3 months ago

SAB BIO Highlights Data in Multiple Presentations at EASD

Sep 3, 2025, 4:05 PM EDT - 3 months ago

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

Aug 7, 2025, 7:30 AM EDT - 4 months ago

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

Jul 21, 2025, 7:30 AM EDT - 5 months ago

SAB BIO Announces Oversubscribed $175 Million Private Placement

May 9, 2025, 9:00 AM EDT - 7 months ago

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

Mar 31, 2025, 7:32 AM EDT - 9 months ago

SAB BIO Reports Full Year 2024 Operating and Financial Results

Jan 28, 2025, 3:40 PM EST - 11 months ago

Why Is SAB BIO Stock Trading Lower On Tuesday?

Jan 28, 2025, 7:00 AM EST - 11 months ago

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

Jan 23, 2025, 7:00 AM EST - 11 months ago

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Nov 6, 2024, 5:05 PM EST - 1 year ago

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

Sep 13, 2024, 7:00 AM EDT - 1 year ago

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

Sep 4, 2024, 7:05 AM EDT - 1 year ago

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

Aug 8, 2024, 5:51 PM EDT - 1 year ago

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

Aug 5, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

Jul 31, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Appoints Lucy To as Chief Financial Officer

Jun 20, 2024, 7:20 AM EDT - 1 year ago

SAb Biotherapeutics Rebrands as SAB BIO

Jun 18, 2024, 1:10 PM EDT - 1 year ago

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

May 30, 2024, 4:45 PM EDT - 1 year ago

SAB Biotherapeutics Announces Departure of Chief Financial Officer

May 21, 2024, 7:15 AM EDT - 1 year ago

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

May 20, 2024, 5:45 PM EDT - 1 year ago

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

May 6, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

Apr 16, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Provides SAB-142 Trial Update

Apr 8, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics to Present at INNODIA Annual Meeting

Apr 4, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Mar 29, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Mar 25, 2024, 10:15 AM EDT - 1 year ago

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

Feb 23, 2024, 8:00 AM EST - 1 year ago

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

Feb 8, 2024, 8:00 AM EST - 2 years ago

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 2, 2024, 7:30 AM EST - 2 years ago

SAB Biotherapeutics Announces Executive Leadership Change

Jan 23, 2024, 5:58 PM EST - 2 years ago

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jan 2, 2024, 4:30 PM EST - 2 years ago

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

Nov 29, 2023, 7:30 AM EST - 2 years ago

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Nov 20, 2023, 7:30 AM EST - 2 years ago

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

Nov 14, 2023, 7:30 AM EST - 2 years ago

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

Nov 14, 2023, 7:15 AM EST - 2 years ago

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

Nov 9, 2023, 7:30 AM EST - 2 years ago

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

stockboyaisle1 Dec. 13 at 10:59 PM

$SABS any news from the Asia conference?

1 · Reply

DDiamond_Handz Dec. 11 at 6:10 PM

$SABS if this isn't a buy signal I dont know what is

0 · Reply

DDiamond_Handz Dec. 10 at 12:37 AM

$SABS before new years, if not shortly after

0 · Reply

JTebow_CWS Dec. 8 at 11:45 PM

$SABS $SABSW $SNY Powerhouse clinical team.

0 · Reply

stockanalysis_ Dec. 8 at 9:27 PM

After Hours Losers: $ORKT $TWG $BDRX $SABS $CMCT Bookmark this page: https://stockanalysis.com/markets/afterhours/losers/?ref=saveontrading

0 · Reply

DDiamond_Handz Dec. 8 at 8:01 PM

$SABS a whale wants cheap shares, should bounce right back

0 · Reply

don_111 Dec. 8 at 7:17 PM

$SABS Getting smoked today. Maybe some are locking profits before the data presentation "just in case"?!

1 · Reply

JTebow_CWS Dec. 8 at 6:31 PM

0 · Reply

Quid_Pro_Quo Dec. 8 at 6:13 PM

$SABS Usually after such a drop a big spike a around the corner

0 · Reply

JTebow_CWS Dec. 8 at 5:19 PM

$SABS https://ir.sab.bio/news-releases/news-release-details/sab-bio-present-data-showcasing-progress-development-sab-142/

0 · Reply

Nicks_pics Dec. 8 at 4:55 PM

$SABS Both my bio’s hit hard this morning on no news 🤷‍♂️. Just violent sector rotation IMO. I haven sold a single share and have no plans to do so.

0 · Reply

DARKP00L Dec. 8 at 1:12 PM

$SABS 08:12 on Dec. 08 2025 SAB Biotherapeutics To Highlight Data Showcasing Progress In Development Of SAB-142 At ATTD-Asia #tradeideas

1 · Reply

Nathaniel_Hoernblower Dec. 5 at 10:26 PM

$SABS Just need the price to come up about $19/share to break even. Not my proudest investment.

1 · Reply

DDiamond_Handz Dec. 5 at 8:06 PM

$SABS

0 · Reply

stockboyaisle1 Dec. 5 at 4:25 AM

$SABS https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/

1 · Reply

JTebow_CWS Dec. 4 at 9:27 PM

$SABS Another TZIELD explanation of being fast tracked. https://youtube.com/shorts/jdcm4klKcag?si=K5Vd09bYmomPdTgX

1 · Reply

Nicxp Dec. 4 at 3:33 PM

$SABS we still loading here?

2 · Reply

JTebow_CWS Dec. 4 at 11:38 AM

$SABS Good info. https://youtu.be/sUIkmSfih7Y?si=PborJzzktDbBhbNE

0 · Reply

Nicks_pics Dec. 3 at 5:07 PM

$SABS Thinking out loud. SAB-142 ATG would allow Novo Nordisk to bypass their proposed encapsulation device needed to prevent recognition of their (hESC) beta cells by the host’s immune system. All it would take is a partnership or buy out. Know what you hold here people. https://therha.org/advancements-in-stem-cell-therapy-for-diabetes-leading-companies-in-2025/

1 · Reply

DDiamond_Handz Dec. 1 at 8:08 PM

$SABS loading up here

1 · Reply

JTebow_CWS Nov. 28 at 10:22 PM

$SABS $SNY https://youtu.be/rfAEzaKDmis?si=17Y9-WgEQJ2ObBxf

0 · Reply

Nicks_pics Nov. 25 at 7:05 PM

$SABS Pinned around $4 for now but volume slowly picking up. It’s likely a different story after $5. Institutional buying is available to a much wider group of funds. I can wait for it, T1D is not going anywhere.

0 · Reply

Market Cap	181.38M
Revenue (ttm)	1.32M
Net Income (ttm)	-34.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,584.09%
Debt to Equity Ratio	0.00

Volume	150,100
Avg Vol	321,456
Day's Range	N/A - N/A
Shares Out	47.61M
Stochastic %K	65%
Beta	0.58
Analysts	Strong Sell
Price Target	$8.83